

Funding

This work was funded by the National Institute for Health and Research Clinical Research Network for North East and Cumbria.

References

1. Peppersack T, Gilles C, Petrovic M *et al.* Prevalence of orthostatic hypotension and relationship with drug use amongst older patients. *Acta Clin Belg* 2013; 68: 107–12.
2. Thompson P, Wright J, Rajkumar C. Non-pharmacological treatments for orthostatic hypotension. *Age Ageing* 2011; 40: 292–3.
3. Perlmutter LC, Sarda G, Casavant V *et al.* A review of orthostatic blood pressure regulation and its association with mood and cognition. *Clin Auton Res* 2012; 22: 99–107.
4. Masaki KH, Schatz IJ, Burchfiel CM *et al.* Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. *Circulation* 1998; 98: 2290–5.
5. Ennis L, Wykes T. Impact of patient involvement in mental health research: longitudinal study. *Br J Psychiatry* 2013; 203: 381–6.
6. Vale CL, Thompson LC, Murphy C *et al.* Involvement of consumers in studies run by the Medical Research Council Clinical Trials Unit: results of a survey. *Trials* 2012; doi: 10.1186/1745-6215-13-9.
7. Involve North East. 2014 <http://www.involve.org.uk/index.php>. (11 November 2013, date last accessed).
8. Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. *Age Ageing* 2012; 41: 587–94.
9. McMurdo ME, Roberts H, Parker S *et al.* Improving recruitment of older people to research through good practice. *Age Ageing* 2011; 40: 659–65.
10. Boote JD, Twiddy M, Baird W *et al.* Supporting public involvement in research design and grant development: a case study of a public involvement award scheme managed by a National Institute for Health Research (NIHR) Research Design Service (RDS). *Health Expect* 2013; doi: 10.1111/hex.12130.
11. Sabaté E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organisation, 2003; 1–211.
12. Schrezenmaier C, Gehrking JA, Hines SM *et al.* Evaluation of orthostatic hypotension: relationship of a new self-report instrument to laboratory-based measures. *Mayo Clin Proc* 2005; 80: 330–4.
13. Kaufmann H, Malamut R, Norcliffe-Kaufmann L *et al.* The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. *Clin Auton Res* 2012; 22: 79–90.

Received 16 April 2014; accepted in revised form 2 May 2014

Age and Ageing 2014; **43**: 868–872
doi: 10.1093/ageing/afu100
Published electronically 19 July 2014

© The Author 2014. Published by Oxford University Press on behalf of the British Geriatrics Society.
All rights reserved. For Permissions, please email: journals.permissions@oup.com

Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia

TOBY SMITH¹, IAN MAIDMENT², JENNIFER HEBDING³, TAIRO MADZIMA³, FRANCINE CHEATER¹, JANE CROSS¹, FIONA POLAND¹, JACQUELINE WHITE⁴, JOHN YOUNG⁵, CHRIS FOX³

¹Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK

²School of Life and Health Sciences, Medicines and Devices in Ageing, Aston Research Centre for Healthy Ageing (ARCHA), Aston University, Birmingham, UK

³Norwich Medical School, University of East Anglia, Norwich, UK

⁴Department of Psychological Health and Wellbeing, Faculty of Health and Social Care, University of Hull, Hull, UK

⁵Bradford Teaching Hospitals NHS Foundation Trust Head, Academic Unit of Elderly Care and Rehabilitation, University of Leeds, Leeds, UK

Address correspondence to: Chris Fox. Tel: (+44) 01 603 593583; Fax: (+44) 01 603 593166. Email: chris.fox@uea.ac.uk

Abstract

Objectives: dementia is a debilitating condition characterised by global loss of cognitive and intellectual functioning, which reduces social and occupational performance. This population frequently presents with medical co-morbidities such as

hypertension, cardiovascular disease and diabetes. The CONSORT statement outlines recommended guidance on reporting of participant characteristics in clinical trials. It is, however, unclear how much these are adhered to in trials assessing people with dementia. This paper assesses the reporting of medical co-morbidities and prescribed medications for people with dementia within randomised controlled trial (RCT) reports.

Design: a systematic review of the published literature from the databases AMED, CINAHL, MEDLINE, EMBASE and the Cochrane Clinical Trial Registry from 1 January 1997 to 9 January 2014 was undertaken in order to identify RCTs detailing baseline medical co-morbidities and prescribed medications. Eligible studies were appraised using the Critical Appraisal Skills Programme (CASP) RCT appraisal tool, and descriptive statistical analyses were calculated to determine point prevalence.

Results: nine trials, including 1474 people with dementia, were identified presenting medical co-morbidity data. These indicated neurological disorders (prevalence 91%), vascular disorders (prevalence 91%), cardiac disorders (prevalence 74%) and ischaemic cerebrovascular disease (prevalence 53%) were most frequently seen.

Conclusions: published RCTs poorly report medical co-morbidities and medications for people with dementia. Future trials should include the report of these items to allow interpretation of whether the results are generalisable to frailer older populations.

PROSPERO Registration: CRD42013006735.

Keywords: *cognitive impairment, dementia, co-morbidity, older people, systematic review*

Introduction

Dementia is a debilitating condition characterised by global loss of cognitive and intellectual functioning, which gradually interferes with social and occupational performance. It is anticipated that the incidence of people with dementia will increase during the next 25 years due to the ageing population [1]. Since dementia is most frequently associated with older people, people with dementia most commonly present with additional co-existing medical conditions. Such co-morbidities may include diabetes, chronic obstructive pulmonary disorder, musculoskeletal disorders and chronic cardiac failure [2].

No studies have previously attempted to determine what the co-morbidities of this group of people are. This is important as it will highlight what the common care needs are, based on a diagnosis of dementia and other medical conditions, which this population share. Given documented difficulties in people with dementia accessing healthcare resources and communicating medical complaints [3], a greater awareness of all the physical and mental health needs of this group of people is important.

The CONSORT statement was developed to improve the reporting of randomised controlled trials (RCTs) published within the literature [4]. Item 15 of the 2010 CONSORT statement emphasises the importance of identifying key variables at baseline which may have prognostic strength of the variables measured. Therefore the reporting of comorbidities in RCTs, can be considered essential practice for people with dementia. Given this importance, the purpose of this paper was to: (1) identify the medical co-morbidities have been reported for people with dementia who have been recruited into trials; and (2) to assess the frequency of reporting for medical co-morbidities within the literature for this population.

Materials and methods

Eligibility criteria

A search of RCTs was undertaken to gain the necessary data to answer this question. All RCTs published from 1 January 1997 to 1 January 2014 which recruited people aged 65 years or over, diagnosed with dementia and presented data on their co-morbidities and/or detailed the medications these people were prescribed, were included. Dementia was defined as any form of dementia (i.e. vascular, multi-infarct, Alzheimers).

Search strategy

An electronic search of the databases AMED, CINAHL, MEDLINE, EMBASE and the Cochrane Clinical Trial Registry was conducted on 9 January 2014. The MEDLINE search strategy is presented in Supplementary data available in *Age and Ageing* online, Table S1. Two review authors reviewed the titles and/or full texts of all identified studies (T.S./I.M.). An iterative search was adopted where initially databases from 2014 to 2007 were searched to identify co-morbidities. The search was extended to 1997, where, no more co-morbidities or medications were identified. It was considered that 'saturation' had been reached, therefore further searches were not required.

Extraction and appraisal

Data were extracted independently by two review authors (J.H./T.M.) using a pre-defined sheet. The quality of the included papers was determined using a modified version of the Critical Appraisal Skills Programme (CASP) RCT study tool [5]. This was undertaken by two reviewers (J.H./T.M.). Any disagreements between the reviewers on data extraction or appraisal were adjudicated by a third reviewer (T.S.).

Data analysis

Each co-morbidity was ranked as a physical or psychological co-morbidity based on the frequency of the condition reported within the literature. The frequency of presentation within the included studies was determined, and the prevalence estimated.

Results

Search results

The search strategy results are presented in Supplementary data available in *Age and Ageing* online, Figure S1. A total of 1234 papers were identified from the search strategy. Following examination, nine papers were eligible and included. The principle reason for exclusion was the absence of data reporting on co-morbidities from study cohorts (94%).

Critical appraisal

Supplementary data available in *Age and Ageing* online, Table S2 summarise the results of the critical appraisal exercise. The evidence was of largely moderate quality with only one study [6] assessed as low quality. Recurrent limitations within the evidence included not clearly documenting how co-morbidities were determined within the cohorts assessed ($n = 7$), not documenting the characteristics of the cohort sufficiently clearly to determine generalisability to the wider population ($n = 8$).

Characteristics of included studies

A summary of the study characteristics is presented in Supplementary data available in *Age and Ageing* online, Table S3. In total 1474 people with dementia were included; 560 males and 914 females. The mean age across the studies ranged from 65 years [7] to 84.4 years [6]. Studies were conducted in the Ukraine [7], Japan [6], Russia [8], Brazil [9], Italy [10], Germany [11], Sweden [12] and the USA [13]. One study was multi-national and was conducted across the Netherlands, Germany, UK and USA [14].

Dementia was diagnosed by a variety of methods. These included the Mini-Mental State Examination (MMSE) [8, 10–14], the National Institute of Neurological and Communicative Disorders and Stroke [7, 8, 10, 11, 14], radiological investigations such as magnetic resonance imaging and computed tomography [7, 8, 11, 13, 14], Diagnostic and Statistical Manual of Mental Disorders—4th edition (DSM-IV) [6, 8, 13], Clinical Dementia Rating [9] and the modified Haschinski Ischaemic Score [8]. Mean impairment scores, as assessed using the MMSE ranged from 6.9 [12] to 24 [14].

Clinical findings

Thirteen co-morbidities were identified from the evidence-base (Table 1). The most prevalent of these was termed

neurological disorders (prevalence 91%), vascular disorders (prevalence 91%), cardiac disorders (prevalence 73%) and depression (prevalence 59%). Sleep apnoea was reported in all 23 people in one study, but this study was specifically investigating this co-morbidity and therefore is not representative of the general population of people with dementia. The least prevalent co-morbidities were cancer (prevalence 11%), diabetes (prevalence 15%) and osteoporosis (prevalence 27%).

Twenty-one prescribed medications were identified. These were divided into four groups: cardiovascular, central nervous system, antithrombotic agents and others, and are presented in Table 2. The others category consisted of calcium supplements, analgesics, gastric ulcer medications, thyroid medications and vitamin K. Overall, there was generally a low prevalence of prescribed medications for this population (Table 2). The most frequently prescribed medications were hypertensive medications, specifically prescribed with a prevalence of 74%. Following this, analgesics (prevalence 30%), anxiolytic drugs (prevalence 37%) and renin-angiotensin drugs were prescribed within the reported cohorts.

Discussion

This paper has provided preliminary information on common co-morbidities that are seen in people with dementia. Cardiovascular pathologies appear to be the most prevalent, based on both the results of co-morbidities reported and prescribed medications from the reported cohorts with dementia. This reflects the findings in elderly populations in general, irrespective of a dementia diagnosis [15]. These findings can be used to better inform clinicians about which conditions they can expect to see exhibited in this population. This is of particular relevance for dementia which can significantly impair a person’s capability to communicate and express their health status.

Table 1. Results of identified comorbidities and prevalence values from included studies

Co-morbidity	Number of studies	Total number of people with/cohort size	Prevalence (%)
Ischaemic cerebrovascular disease	2	49/92	53
Hypertension	2	121/255	47
Cardiovascular	2	79/193	41
Diabetes mellitus	2	29/193	15
Depression	2	113/193	59
Vascular disorder	1	368/404	91
Hypercholesterolaemia	1	79/225	35
Osteoporosis	1	61/225	27
Neurological disorder	1	368/404	91
Cardiac disorder	1	298/404	74
Cancer	1	7/62	11
Psychosis	1	41/132	31
Sleep apnoea	1	23/23	100

Table 2. Prescribed medications people with dementia were documented as receiving in included studies

Medication	Number of studies	Total number of people with/cohort size	Prevalence (%)
.....			
Cardiovascular medicines			
Renin–angiotensin drugs	3	165/464	36
Ca-antagonists	2	23/434	5
Beta-blockers	1	42/404	10
Termed ‘hypertensive medications’	1	73/98	74
Vasodilators	1	3/30	10
Central nervous system medicines			
Antidepressants	2	42/94	45
Anxiolytic drugs	1	36/98	37
Psychoactive medications	1	23/98	23
Antipsychotics	1	3/30	10
Sedatives	1	3/30	10
Antithrombotic agents			
Antithrombotic agents	2	34/434	8
Antiplatelet drugs	1	22/98	22
Others			
Calcium supplements	1	3/30	10
Analgesics	1	9/30	30
Peptic ulcer drugs	1	6/30	20
Vitamin K	1	3/30	10
Thyroid therapy	1	3/30	10
Benign prostatic hypertrophy drugs	1	3/30	10

The results are based on RCT data, and consequently these findings are likely to be based on a self-selecting sample of the population with dementia through two means. Firstly, only people eligible to participate in the included trials would have been included in our analysis. Accordingly, people with an active infection, such as a urinary tract infection, those with unstable cardiovascular status, or those taking medications with contraindications for an experimental intervention would have been excluded. Therefore, a number of important co-morbidities or medications may have been omitted from the review. Secondly, as the results are based on clinical trial populations, a proportion of participants and/or their carers may be disengaged from participating in a clinical trial due to social or environmental factors [16]. Accordingly, this population may have presented with different medical co-morbidities or prescribed medications.

The findings acknowledge the poor reporting of co-morbidities and prescribed medications. While nine papers presented data on the overall medical status and co-morbidities exhibited by their study cohorts, 15 otherwise eligible papers did not present this data. As well as limiting the possible data set available for this review, this raises a major issue about potential study generalisability of previous clinical trials in dementia research. Not fully appreciating the medical status and co-morbidities of cohorts means that the reader is unable to fully generalise the findings of a specific trial to their own patient group. Furthermore, interventions

such as medication or physical activity may be more or less effective for some specific participant groups dependent on their co-morbidities. Therefore, a major recommendation is that medical co-morbidities should be more widely reported within the description of cohort characteristics.

There was variable terminology in co-morbidities. For example, vascular, cardiac and neurological disorders were terms used in Ihl *et al.* [7]; these terms provide an indication of the general medical co-morbidity, but do not specifically describe exactly which medical conditions are associated with this pathology. Similarly, medication usage was poorly reported with a lack of standardisation making it difficult to compare usage between the different studies. Some of the terminology used was imprecise with the potential for confusion. For example, Doody *et al.* [8] included the classification ‘psychoactive drugs’ which, although not defined, appeared to include antidepressants, sedatives, hypnotic and antipsychotics. The same study included the classification anxiolytic, however, the difference between an anxiolytic and a psychoactive drug was not clearly stated. Both co-morbidities and medication usage should therefore be reported in a standardised fashion, for example, using the WHO Anatomical Therapeutic Chemical classification system (http://www.whocc.no/atc_ddd_index/) for medications.

Key points

- Dementia is a growing health challenge for primary and secondary care providers worldwide.
- CONSORT statement recommends participant demographic information be provided to ease trial generalisability.
- Currently, medical co-morbidities and medicine prescribing is poorly reported in randomised controlled trials in dementia.
- Future research must address this limitation to improve reporting of medical comorbidities and prescribed medications.

Supplementary data

Supplementary data mentioned in the text is available to subscribers in *Age and Ageing* online.

References

1. Thomas K, Stobbart Rowlands M, Giles L. Meeting the prime minister's dementia challenge: improving care and increasing ACP discussions for people with dementia following the gold standards framework (GSF) dementia care training programme. *BMJ Support Palliat Care* 2013; 3: 288–9.
2. Helvik AS, Engedal K, Benth JS, Selbæk G. A 52 month follow-up of functional decline in nursing home residents—degree of dementia contributes. *BMC Geriatr* 2014; 14: 45.
3. Healthcare at Home. Understanding out of hospital dementia care report 2011. Available at: http://www.hah.co.uk/sites/default/files/upload/files/HAH_Report_web.pdf (16 April 2014, date last accessed).

4. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Intern Med* 2010; 152: 726–32.
5. Critical Appraisal Skills Programme—Randomised Controlled Trial Tool. Available at: <http://www.casp-uk.net/#!casp-tools-checklists/c18f8> (3 January 2014, date last accessed).
6. Iwasaki K, Kobayashi S, Chimura Y *et al.* A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine ‘ba wei di huang wan’ in the treatment of dementia. *J Am Geriatr Soc* 2004; 52: 1518–21.
7. Ihl R, Tribanek M, Bachinskaya N. Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial. *J Neurol Sci* 2010; 299: 184–7.
8. Doody RS, Gavrilova SI, Sano M *et al.* Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. *Lancet* 2008; 372: 207–15.
9. Moraes W, Poyares D, Sukys-Claudino L, Guilleminault C, Tufik S. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. *Chest* 2008; 133: 677–83.
10. Scarpini E, Bruno G, Zappalà G *et al.* Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer’s disease: a randomized, double blind, placebo controlled withdrawal trial. *J Alzheimers Dis* 2011; 26: 211–20.
11. del Ser T, Steinwachs KC, Gertz HJ *et al.* Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study. *J Alzheimers Dis* 2013; 33: 205–15.
12. Stenvall M, Berggren M, Lundström M, Gustafson Y, Olofsson B. A multidisciplinary intervention program improved the outcome after hip fracture for people with dementia—subgroup analyses of a randomized controlled trial. *Arch Gerontol Geriatr* 2012; 54: e284–9.
13. Trzepacz PT, Cummings J, Konechnik T *et al.* Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease. *Int Psychogeriatr* 2013; 25: 707–19.
14. Scheltens P, Kamphuis PJ, Verhey FR *et al.* Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. *Alzheimers Dement* 2010; 6: 1–10.e1.
15. Eckert KA, Shi Z, Taylor AW, Wittert G, Price K, Goldney RD. Learning from an epidemiological, population-based study on prescribed medicine use in adults. *Pharmacoepidemiol Drug Saf* 2013; 22: 271–7.
16. Kaur G, Smyth RL, Williamson P. Developing a survey of barriers and facilitators to recruitment in randomized controlled trials. *Trials* 2012; 13: 218.

Received 16 April 2014; accepted in revised form 2 May 2014

Age and Ageing 2014; **43**: 872–876
doi: 10.1093/ageing/afu086
Published electronically 30 June 2014

© The Author 2014. Published by Oxford University Press on behalf of the British Geriatrics Society.
All rights reserved. For Permissions, please email: journals.permissions@oup.com

Compliance with trial registration in five core journals of clinical geriatrics: a survey of original publications on randomised controlled trials from 2008 to 2012

EVA MANN¹, NATALIE NGUYEN², STEFFEN FLEISCHER², GABRIELE MEYER²

¹Institute of General Medicine, Family Medicine and Preventive Medicine, Paracelsus Medical University, Strubergasse 21, Salzburg 5020, Austria

²Institute of Health and Nursing Science, Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany

Address correspondence to: E. Mann. Tel: (+43) 664 2621397; Fax: (+43) 5522 431339. Email: evamann@vol.at

Abstract

Objective: to assess the proportion of registered randomised controlled trials in five core clinical geriatric journals and to analyse whether registered study outcomes correspond with published outcomes.